Protocol for the Stimulating &#946;<sub>3</sub>-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease.

Author: AitkenSarah Joy, AliZara S, BillotLaurent, BubbKristen J, ChowClara, FigtreeGemma A, FinemoreMeghan, GolledgeJonathan, GrayMichael P, GrieveStuart M, HamburgNaomi, HarmerJason A, KeechAnthony C, MisterRebecca, PatelSanjay, PuttaswamyVikram

Paper Details 
Original Abstract of the Article :
Label="INTRODUCTION">There is currently only one approved medication effective at improving walking distance in people with intermittent claudication. Preclinical data suggest that the &#946;<sub>3</sub>-adrenergic receptor agonist (mirabegron) could be repurposed to treat intermittent claudication ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479946/

データ提供:米国国立医学図書館(NLM)

Mirabegron: A Potential New Weapon in the Fight Against Peripheral Artery Disease

Peripheral artery disease (PAD), a condition that affects blood flow to the limbs, often leads to debilitating pain and limited mobility. This study explores the potential of mirabegron, a medication typically used to treat overactive bladder, to improve walking distance in individuals with PAD. Much like a camel, guided by an ancient map, the researchers sought to find new routes for treating PAD, exploring uncharted territory in the field of drug repurposing.

Mirabegron: A New Path to Improved Mobility

The STAR-PAD trial, designed to assess the effectiveness of mirabegron in treating PAD, holds great promise. The researchers believe that mirabegron, by targeting a specific type of receptor, could provide a novel approach to improving walking distance and enhancing quality of life for PAD patients. This potential breakthrough, much like the discovery of a new oasis, offers hope for a more comfortable and active life for individuals with PAD.

A New Era for PAD Treatment

This study opens the door to a new era of PAD treatment, potentially broadening the therapeutic landscape and offering new hope for individuals seeking improved mobility. Imagine a camel, equipped with a new and efficient water-finding mechanism, now able to navigate the desert with greater ease and stability. This study offers a similar vision for PAD management, providing a potential path towards better control and improved quality of life.

Dr.Camel's Conclusion

This study explores the potential of repurposing mirabegron, a medication currently used for overactive bladder, as a novel treatment for peripheral artery disease. The STAR-PAD trial aims to assess whether mirabegron can improve walking distance in individuals with PAD, offering a potential breakthrough in managing this debilitating condition. This research underscores the ongoing quest for new and effective therapies to improve quality of life for those affected by PAD.

Date :
  1. Date Completed 2021-11-02
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34588252

DOI: Digital Object Identifier

PMC8479946

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.